Full-Time

Associate Director

Patient Support Services

Updated on 9/4/2026

Acadia Pharmaceuticals

Acadia Pharmaceuticals

1,001-5,000 employees

Develops and commercializes CNS disorder therapies

Compensation Overview

$144k - $180k/yr

+ Discretionary bonus + Equity awards

Princeton, NJ, USA + 1 more

More locations: San Diego, CA, USA

Hybrid

Three days in the office per week on average; the role is based in San Diego or Princeton.

Bachelor's

Category
Growth & Marketing (1)
Required Skills
Market Research

Get referred to Acadia Pharmaceuticals

See people who can refer or advise you

Requirements
  • A bachelor's degree with 8+ years of experience in patient support services, program strategy, and healthcare operations within pharmaceutical or biotechnology organizations.
  • Experience with specialty medications, including rare disease and neuropsychiatric products.
  • Proven project management experience.
  • Outstanding customer relationship, interpersonal, and communication skills, with the ability to communicate across diverse audiences and influence cross-functionally.
  • Proven success in high-impact program development and execution.
  • A patient-centric and service-oriented mindset.
  • The ability to work effectively as part of a team, with strong self-awareness and interpersonal skills.
  • A results-oriented, detail-focused, accurate, prompt, and deadline-conscious approach.
  • The ability to drive multiple projects simultaneously and deliver results.
  • The ability to influence others without authority and partner successfully with cross-functional teams.
  • Business acumen and budgeting skills.
  • Strong presentation skills.
  • The ability to adapt to an environment of change.
  • The ability to travel 30%.
Responsibilities
  • Partner with Patient Support Services field team members to evolve and improve services and execute hub and other Patient Support Services strategies across the portfolio, with a focus on Neuroscience.
  • Collaborate with internal partners on relevant market research and lead Patient Support Services projects to refine strategies and generate insights that create or optimize programs for healthcare professionals and patients.
  • Help lead the planning, development, and implementation of access marketing strategies, programs, tactics, and messaging.
  • Ensure that the access services marketing plan and execution align with Brand Marketing and Access & Reimbursement strategies.
  • Support the access-related Brand Planning process.
  • Collaborate with Brand Marketing to ensure a seamless customer experience and alignment with brand initiatives.
  • Plan and develop hub priorities, content, tools, and training for national meetings and customer-facing team training.
  • Serve as an access services expert and recommend solutions to address unmet needs across the portfolio, with a focus on Neuroscience.
  • Help lead the planning, development, and management of the access website, materials, messaging, and programming, including copay programs, sample programs, reimbursement, and patient financial support services.
  • Develop and track key performance indicators and continually assess and monitor the impact and execution of access services across the portfolio, including feedback from service users and internal stakeholders.
  • Attend professional, provider, and patient conferences and stay current on innovation.
  • Manage vendor relationships to ensure customer service, quality delivery, and budget oversight.
  • Collaborate with the Field Access team on process development, operations management, and ongoing training needs.
  • Create and present relevant data and presentations for business reviews and other key meetings.
  • Collaborate with Access & Reimbursement, Specialty Trade and Distribution, Brand Marketing, Sales, Field Access, and Patient Advocacy teams to optimize offerings and services.
  • Collaborate with internal and external partners to ensure that all programs meet legal, regulatory, and compliance standards.
Desired Qualifications
  • Medicare Part D experience.
  • Agency or vendor management experience, including briefing, execution, and budgetary oversight.
Acadia Pharmaceuticals

Acadia Pharmaceuticals

View

ACADIA Pharmaceuticals develops and commercializes medicines for central nervous system (CNS) disorders, focusing on neurological and psychiatric conditions with unmet medical needs. Its work centers on identifying drug candidates, advancing them through preclinical and clinical trials, and, upon regulatory approval, bringing therapies to market. Its products address CNS conditions such as Parkinson's disease psychosis, reflecting a commitment to treating complex brain disorders. The company combines in-house research with potential strategic collaborations to expand its portfolio and reach. Unlike peers that rely on a single development path, ACADIA emphasizes a broad pipeline and the ability to commercialize approved therapies, aiming to provide effective CNS treatments to patients and improve outcomes in mental health and neuroscience.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

San Diego, California

Founded

1993

Get referred to Acadia Pharmaceuticals

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Acadia raised 2026 revenue guidance to $1.24 billion-$1.30 billion after second-quarter strength.
  • DAYBUE sales jumped 30% year over year to $125 million, driven by STIX.
  • European approval unlocks Germany launch in early Q4 2026 and milestone payments from Neuren.

What critics are saying

  • Nuplazid trial-misrepresentation litigation heads toward jury, risking damages and disclosure burdens in 2026.
  • DAYBUE depends on a narrow Rett market; STIX concentration leaves execution exposed.
  • If remlifanserin misses September 2026 topline data, Acadia loses its next-growth narrative.

What makes Acadia Pharmaceuticals unique

  • DAYBUE is Europe’s first and only Rett syndrome treatment after August 2026 approval.
  • Nuplazid still anchors Acadia’s CNS franchise with $183 million second-quarter 2026 sales.
  • Remlifanserin targets Alzheimer’s disease psychosis, opening a second blockbuster-sized neurological market.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Employee Stock Purchase Plan

Paid Vacation

Paid Holidays

Paid Sick Leave

Paid Parental Leave

Tuition Reimbursement

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

2%

2 year growth

0%
Daily Dispatch
Aug 25th, 2026
Neuren secures European approval for Rett syndrome treatment.

Neuren secures European approval for Rett syndrome treatment. Neuren Pharmaceuticals has reached a major milestone in the global commercialisation of trofinetide after the European Commission granted marketing authorisation for DAYBU to treat neurobehavioural symptoms associated with Rett syndrome. The approval makes DAYBU the first and only authorised treatment for Rett syndrome in the European Union, extending access to patients aged five years and older across all 27 EU member states as well as Iceland, Liechtenstein and Norway. For the Melbourne-based biotechnology company, the decision represents both an important advance for families affected by the rare neurological disorder and a potentially material commercial catalyst under its licensing arrangement with Acadia Pharmaceuticals. Acadia, which holds Neuren's exclusive worldwide licence to develop and commercialise trofinetide, has previously indicated that it expects to launch DAYBU in Germany in early in the fourth quarter of 2026. Neuren chief executive Jon Pilcher said the approval was especially meaningful given the absence of an approved Rett syndrome treatment in Europe until now. "We are delighted for the Rett syndrome community in Europe, who, until now, have had no approved treatment for this devastating condition," Pilcher said. "The European Commission's approval of DAYBU is particularly rewarding for Neuren given our long-standing commitment to developing therapies for serious neurological disorders with profound unmet need." Rett syndrome is a severe genetic neurodevelopmental condition that predominantly affects girls and can lead to profound impairments in communication, motor function and everyday functioning. The European approval allows DAYBU to be marketed for the treatment of its neurobehavioural symptoms, creating a new treatment option for patients and families across the region. The decision also brings financial significance for Neuren. Under its European licence agreement with Acadia, Neuren is entitled to receive US$35 million following the first commercial sale of DAYBU in Europe. It could also receive up to US$170 million in sales milestone payments as annual net sales reach escalating thresholds, alongside tiered royalties ranging from the mid-teens to the low 20 per cent range. DAYBUE oral solution is already approved for Rett syndrome in the United States, Canada and Israel, while DAYBUE STIX powder has been approved by the US Food and Drug Administration. Trofinetide is not approved for sale in Australia. The European authorisation comes as Neuren continues to advance its broader pipeline of therapies for serious neurological disorders. Its investigational candidate NNZ-2591, also known as ercanetide, is in clinical development for several rare neurodevelopmental conditions, including Phelan-McDermid syndrome, Pitt Hopkins syndrome and Angelman syndrome. Neuren is also developing NNZ-2591 for hypoxic ischaemic encephalopathy, a form of brain injury that can occur before or shortly after birth. The company is currently running its Phase 3 Koala trial, a randomised, double blind and placebo-controlled study assessing NNZ-2591 in children aged three to 12 years with Phelan-McDermid syndrome, alongside a 52-week open-label extension study.

News Break! Middle East
Aug 12th, 2026
ADARx Pharmaceuticals expands leadership team with Board and executive appointments.

ADARx Pharmaceuticals expands leadership team with Board and executive appointments. - Ying Huang, Ph.D. appointed to Board of Directors, bringing deep experience spanning executive public biotech leadership, Wall Street and big pharma R&D - - Robert Ackles joins as Chief People Officer, bringing nearly three decades of biopharma leadership experience and a proven record of building people strategies that support growth, culture and execution - SAN DIEGO, Aug. 12, 2026 (GLOBE NEWSWIRE) - ADARx Pharmaceuticals, Inc. (ADARx), a late-stage clinical biotechnology company developing next-generation siRNA therapeutics, announced today that it is expanding its leadership team with the appointment of Ying Huang, Ph.D. to its Board of Directors and Robert Ackles as its Chief People Officer. These key additions to the leadership team will help guide strategic growth as ADARx advances multiple siRNA clinical programs across therapeutic areas. "Dr. Huang has deep experience spanning drug development, capital markets and company building. Having led a pioneering genetic medicines company through its evolution into a fully integrated commercial biopharmaceutical organization, he brings a uniquely broad strategic perspective that will be invaluable as we aim to unlock the potential of our RNA platform and advance multiple programs through mid- and late-stage clinical development," said Dr. Zhen Li, President and Chief Executive Officer of ADARx. "We are also excited to welcome Rob to our executive team as our inaugural Chief People Officer. Developing and supporting our exceptional team as we scale the organization for our next stage of growth is essential to achieving our mission. Rob's experience building high-performing teams and guiding organizations through various stages of growth will help to strengthen our culture and position us for continued success." Dr. Huang is Chief Executive Officer (CEO) of K2 Therapeutics. Previously, he served as CEO of Legend Biotech Corporation from 2020 to 2026 and as its Chief Financial Officer from 2019 until 2022. Prior to Legend, Dr. Huang spent more than a decade as a biotechnology analyst, most recently as Managing Director and Head of Biotech Equity Research at BofA Securities, Inc. and previously at Wachovia, Credit Suisse, Gleacher and Barclays. Prior to his Wall Street career, Dr. Huang was a Principal Scientist at Schering-Plough in the Department of Chemical Research. Dr. Huang is also the co-author of multiple patents and peer-reviewed publications. Dr. Huang currently serves as a director of Quanta Therapeutics, Inc. and Third Arc Bio. Dr. Huang received his M.A., M.Phil. and Ph.D. in Chemistry from Columbia University. Dr. Huang also studied at Columbia Business School and in the Special Class for the Gifted Young at the University of Science and Technology of China. "RNA medicines have transformed our ability to address disease by reaching targets that were previously inaccessible. ADARx's next-generation siRNA technologies and its talented team are well positioned to advance the field, and the company has made exciting progress across its siRNA platform and pipeline," said Dr. Huang. "I am honored to be joining the Board and look forward to working with the leadership team and fellow Board members to help shape the company's strategy and support its continued growth as it works to make a life-changing impact for patients." Mr. Ackles brings nearly three decades of biopharmaceutical leadership experience and a proven record of building people strategies that support growth, culture, and execution. He has helped guide organizations across start-up, emerging, and rapid-growth stages, contributing to the advancement of both clinical and commercial priorities. Mr. Ackles joins ADARx after previously serving for 10 years as Senior Vice President, Chief People Officer at Acadia Pharmaceuticals, where he led human resources and talent initiatives as a member of the executive leadership team. During his tenure, he supported Acadia's growth and organizational evolution while helping strengthen a high-performance culture. Earlier in his career, Mr. Ackles held leadership roles at Santarus Pharmaceuticals and TAP Pharmaceuticals, with experience spanning human resources, organizational design, talent development, commercial management, and specialty market sales. Mr. Ackles received a Bachelor of Arts in Psychology from the University of California, Santa Barbara. "The opportunity to join a company with such a compelling mission and exceptional team is incredibly exciting," said Mr. Ackles. "As we continue to execute across the business, I look forward to partnering across the organization to build on the strong foundation in place, strengthen our organizational capabilities and foster a culture that empowers our people to achieve the important milestones ahead." About ADARx Pharmaceuticals ADARx Pharmaceuticals, Inc. is a late-stage biotechnology company dedicated to transforming cutting-edge science into next-generation siRNA therapeutics. News Break Middle East has developed technology designed to control the expression of specific disease drivers with highly selective RNA targeted therapies with the goal of delivering life-changing treatments for patients with urgent unmet medical needs. ADARx is focused on advancing and expanding a deep pipeline of highly potent, durable and selective RNA-targeted therapeutic candidates, developing product candidates for the treatment of complement-mediated, genetic, cardiovascular, thrombosis, central nervous system and metabolic (obesity) diseases. In addition to its wholly-owned programs, News Break Middle East has entered into a collaboration and license option agreement with AbbVie to develop small interfering RNA (siRNA) therapeutics across multiple disease areas, including neuroscience, immunology and oncology. Follow ADARx on LinkedIn. Contacts Investors: [email protected] Media: [email protected] Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. News Break Middle East do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Pharma Dispatch
Aug 6th, 2026
Neuren reports record DAYBUE sales as royalties rise and global expansion nears.

Neuren reports record DAYBUE sales as royalties rise and global expansion nears. Australian company Neuren Pharmaceuticals has reported a record quarter for DAYBUE (trofinetide), with its partner, Acadia Pharmaceuticals, reporting net sales of US$125 million in the second quarter of 2026... Latest video. Follow PharmaDispatch.

Daily Dispatch
Aug 5th, 2026
Neuren reports record DAYBUE sales as royalties rise and global expansion nears.

Neuren reports record DAYBUE sales as royalties rise and global expansion nears. Neuren Pharmaceuticals has reported a record quarter for DAYBUE (trofinetide), with its partner Acadia Pharmaceuticals recording net sales of US$125 million in the second quarter of 2026. The result marks a 30 per cent increase from the same quarter last year and a 24 per cent rise from the first quarter of 2026. It is the highest quarterly sales result for DAYBUE since its launch and was driven almost entirely by increased patient volume. Acadia has also raised its full-year 2026 DAYBUE sales guidance to between US$480 million and US$510 million, up from its previous forecast of US$460 million to US$490 million. Based on the revised guidance, Neuren now expects royalty income for the year of between US$53 million and US$56 million, compared with its earlier estimate of US$50 million to US$54 million. Neuren earned US$12.9 million in royalties during the second quarter, representing a 34 per cent increase from the second quarter of 2025 and a 24 per cent rise from the previous quarter. The company attributed much of the sales momentum to DAYBUE STIX, a powder formulation of trofinetide that became broadly available in the United States in early April. After an initial limited launch through Rett syndrome Centres of Excellence during the first quarter, demand for STIX strengthened in the second quarter. By the end of June, 40 per cent of all DAYBUE patients in the United States were receiving STIX. About 45 per cent of STIX demand during the quarter came from new or returning patients, suggesting that the formulation is supporting both the continued treatment of existing patients and the expansion of the overall patient base. Neuren CEO Jon Pilcher commented: "We are pleased to see an exceptional quarter for DAYBUE, with very strong sales volume growth reflecting the early success of STIX in the US, as well as achievement of the positive CHMP opinion - both important steps toward bringing trofinetide to more patients with Rett syndrome globally. Subject to approval being confirmed, we now look forward to Acadia's anticipated European launch later this year." The company is also preparing for a potential European launch. In late June, the Committee for Medicinal Products for Human Use adopted a positive opinion following a reexamination procedure, recommending that the European Commission grant marketing authorisation for DAYBUE to treat neurobehavioral symptoms associated with Rett syndrome in adults and children aged five years and older. If approved by the European Commission, the authorisation would cover all 27 European Union member states, along with Iceland, Liechtenstein and Norway. Acadia is expected to launch DAYBUE in Germany in early October through December 2026. Under the European licensing agreement, Neuren would receive US$35 million following the first commercial sale. The company is also eligible for up to US$170 million in sales milestone payments as annual net sales reach specified thresholds, in addition to tiered royalties ranging from the mid-teens to the low twenties as a percentage of net sales. In Japan, the topline results from an ongoing trofinetide clinical trial remain on track for release between September and November 2026. Neuren anticipates submitting a regulatory application in Japan during 2027. Acadia has reaffirmed its target of achieving US$700 million in DAYBUE net sales in 2028. The updated outlook reflects growing demand in the United States, the potential European launch and further international development. Neuren has granted Acadia an exclusive worldwide licence to develop and commercialise trofinetide. DAYBUE oral solution is approved in the United States, Canada and Israel, while DAYBUE STIX powder is approved by the United States Food and Drug Administration for the treatment of Rett syndrome.

MarketBeat
Jul 15th, 2026
Emerald Advisers LLC has $637,000 stock holdings in ACADIA Pharmaceuticals Inc. $ACAD.

Emerald Advisers LLC has $637,000 stock holdings in ACADIA Pharmaceuticals Inc. $ACAD. July 15, 2026 Key points. * Emerald Advisers LLC cut its ACADIA Pharmaceuticals stake by 96.5% in the first quarter, leaving it with 28,637 shares worth about $637,000. * ACADIA reported Q1 earnings of $0.02 per share, missing estimates of $0.04, while revenue of $268.1 million also came in below expectations. Revenue still rose 9.7% year over year. * Analysts remain mostly positive on the stock, with a consensus rating of Moderate Buy and an average price target of $32.94. Recent insider activity showed executives selling shares, while institutional investors still own 96.71% of the company. * Five stocks to consider instead of ACADIA Pharmaceuticals. Emerald Advisers LLC trimmed its stake in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 96.5% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 28,637 shares of the biopharmaceutical company's stock after selling 782,560 shares during the quarter. Emerald Advisers LLC's holdings in ACADIA Pharmaceuticals were worth $637,000 at the end of the most recent reporting period. Several other institutional investors and hedge funds have also recently modified their holdings of ACAD. State Street Corp lifted its stake in shares of ACADIA Pharmaceuticals by 9.0% during the 4th quarter. State Street Corp now owns 7,910,733 shares of the biopharmaceutical company's stock worth $211,296,000 after buying an additional 655,257 shares during the last quarter. Geode Capital Management LLC grew its stake in ACADIA Pharmaceuticals by 3.4% in the 4th quarter. Geode Capital Management LLC now owns 3,239,451 shares of the biopharmaceutical company's stock valued at $86,539,000 after buying an additional 106,807 shares during the last quarter. Dimensional Fund Advisors LP grew its stake in ACADIA Pharmaceuticals by 4.4% in the 4th quarter. Dimensional Fund Advisors LP now owns 2,920,974 shares of the biopharmaceutical company's stock valued at $78,019,000 after buying an additional 122,840 shares during the last quarter. Marshall Wace LLP raised its holdings in ACADIA Pharmaceuticals by 19.8% in the 3rd quarter. Marshall Wace LLP now owns 2,358,881 shares of the biopharmaceutical company's stock valued at $50,339,000 after acquiring an additional 389,170 shares during the period. Finally, First Trust Advisors LP raised its holdings in ACADIA Pharmaceuticals by 16.8% in the 4th quarter. First Trust Advisors LP now owns 2,270,034 shares of the biopharmaceutical company's stock valued at $60,633,000 after acquiring an additional 326,882 shares during the period. 96.71% of the stock is currently owned by institutional investors and hedge funds. ACADIA Pharmaceuticals trading down 0.0%. Shares of ACAD opened at $25.49 on Wednesday. ACADIA Pharmaceuticals Inc. has a 12 month low of $19.69 and a 12 month high of $28.35. The firm's 50 day moving average is $22.70 and its 200-day moving average is $23.33. The stock has a market capitalization of $4.36 billion, a PE ratio of 11.59, a P/E/G ratio of 18.37 and a beta of 0.80. ACADIA Pharmaceuticals (NASDAQ:ACAD - Get Free Report) last issued its quarterly earnings results on Wednesday, May 6th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by ($0.02). The company had revenue of $268.10 million during the quarter, compared to the consensus estimate of $280.25 million. ACADIA Pharmaceuticals had a net margin of 34.30% and a return on equity of 9.61%. The company's quarterly revenue was up 9.7% on a year-over-year basis. During the same quarter last year, the firm posted $0.11 earnings per share. Equities research analysts predict that ACADIA Pharmaceuticals Inc. will post 0.37 earnings per share for the current fiscal year. Insiders place their bets. In other ACADIA Pharmaceuticals news, insider James Kihara sold 5,401 shares of ACADIA Pharmaceuticals stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $21.18, for a total value of $114,393.18. Following the completion of the transaction, the insider directly owned 24,509 shares of the company's stock, valued at $519,100.62. The trade was a 18.06% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Mark C. Schneyer sold 3,506 shares of the company's stock in a transaction on Monday, May 4th. The shares were sold at an average price of $21.79, for a total value of $76,395.74. Following the sale, the executive vice president owned 66,145 shares of the company's stock, valued at approximately $1,441,299.55. The trade was a 5.03% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 10,239 shares of company stock worth $219,813. Corporate insiders own 26.20% of the company's stock. Wall Street analyst weigh in. ACAD has been the subject of a number of research analyst reports. Deutsche Bank Aktiengesellschaft restated a "buy" rating and set a $37.00 price objective on shares of ACADIA Pharmaceuticals in a report on Monday, June 29th. Bank of America increased their target price on ACADIA Pharmaceuticals from $29.00 to $30.00 and gave the stock a "buy" rating in a research note on Tuesday, June 30th. HC Wainwright cut ACADIA Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Tuesday, June 30th. Royal Bank Of Canada boosted their price target on ACADIA Pharmaceuticals from $29.00 to $36.00 and gave the company an "outperform" rating in a research note on Tuesday, July 7th. Finally, Weiss Ratings lowered ACADIA Pharmaceuticals from a "hold (c+)" rating to a "hold (c)" rating in a report on Friday, May 1st. Twelve investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $32.94. About ACADIA Pharmaceuticals. ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA's research centers concentrate on conditions with significant unmet medical needs, including Parkinson's disease psychosis, Alzheimer's disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics. The company's flagship product, NUPLAZID(R)(pimavanserin), received U.S. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider ACADIA Pharmaceuticals, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ACADIA Pharmaceuticals wasn't on the list. While ACADIA Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.